Philips Medical Systems (Cleveland) Inc – FDA Warning Letter
On June 7, 2011, the FDA issued a Warning Letter to Philips Medical Systems (Cleveland) Inc. following an inspection from August 25 to December 3, 2010. The inspection revealed that the firm's Brilliance, Big Bore, iCT, MX-16 Slice Families of CT products, and Gemini, Gemini LXL/TF, BrightView, JetStream, and Precedence Families of NM products were adulterated under 21 U.S.C. § 351(h) due to non-conformity with Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation (21 CFR Part 820).
Key violations included: 1. **Failure to establish and maintain adequate CAPA procedures (21 CFR 820.100(a))**: Issues like incorrect HCOR Scaling for infant scans were not managed through the CAPA system, leading to delayed implementation of fixes. 2. **Failure to implement and record changes for quality problems (21 CFR 820.100(a)(5))**: The firm continued using unbaked anode/cathode power modules despite identified moisture ingress and a supplier's corrective action. 3. **Failure to investigate nonconformities (21 CFR 820.100(a)(2))**: CAPA 10-0
- Product type
- Devices
ID · d54511a7-f934-455f-bd29-927a6c8cef65
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.